Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tariq Yousuf

Internal Medicine Sherman, TX Medical Doctor

NPI 1730509472 CMS profile 2792475

425 N Highland Ave Ste 220, Sherman, TX 75092

Open in the dashboard

General payments

$11,226

313 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$64,340 paid to institutions, not to them · program year 2025

Through program year 2025, Tariq Yousuf of Sherman, TX is reported in the CMS Open Payments database as having received $11,226 across 313 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $64,340 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,866 66
2024 General $1,137 61
2023 General $2,902 74
2022 General $2,965 74
2021 General $1,179 25
2020 General $629 5
2019 General $548 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tariq Yousuf
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Tariq Yousuf were reported at $1,866. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Tariq Yousuf Internal Medicine median Middle half National median
2019 $548 $159 $48–$570 $163
2020 $629 $119 $33–$402 $114
2021 $1,179 $135 $37–$521 $132
2022 $2,965 $141 $42–$496 $149
2023 $2,902 $149 $45–$519 $160
2024 $1,137 $154 $47–$537 $164
2025 $1,866 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $2,764 71 payments
  2. AngioDynamics, Inc. $1,891 8 payments
  3. Abbott Laboratories $1,096 23 payments
  4. Biotronik Inc. $982 71 payments
  5. AOP Health US, LLC $527 1 payment
  6. Pfizer Inc. $485 23 payments
  7. Novartis Pharmaceuticals Corporation $417 22 payments
  8. Terumo Medical Corporation $338 3 payments
  9. Cardiovascular Systems Inc. $301 9 payments
  10. Cook Medical LLC $237 2 payments
  11. Other $2,189 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,087 294 payments
  2. Travel and Lodging $3,447 14 payments
  3. Education $692 5 payments
Products named General payments · program years 2019–2025
  1. VenaCure 1470 Pro $1,891 8 payments
  2. (9520) IGT Devices Undivided $1,480 9 payments
  3. Rapiblyk Cardiovascular $527 1 payment
  4. Rapiblyk Cardiovascular $527 1 payment
  5. Pulsar-18 T3 $502 36 payments
  6. Passeo-18 $449 33 payments
  7. GLIDESHEATH SLENDER $319 2 payments
  8. LEQVIO $299 16 payments
  9. Diamondback Peripheral $288 8 payments
  10. ELIQUIS $259 11 payments
  11. Other $5,995 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

3,885

Median for Internal Medicine: 777

Drug cost

$422,087

Median for Internal Medicine: $73,373

Branded share of claims

29.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 284 $247,807
Xarelto Rivaroxaban Brand 90 $70,532
Repatha Sureclick Evolocumab Brand 38 $24,120
Brilinta Ticagrelor Brand 37 $23,389
Farxiga Dapagliflozin Propanediol Brand 20 $20,476
Ranolazine Er Ranolazine Brand 74 $5,376
Clopidogrel Clopidogrel Bisulfate Brand 512 $4,283
Rosuvastatin Calcium Generic 335 $3,490
Metoprolol Succinate Generic 391 $3,401
Midodrine Hcl Generic 15 $2,133

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$1,706,930

Of which drugs: $6,266

Medicare patients

1,040

Average age 74

Services billed

14,781

558 women, 482 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 50%
Diabetes 41%
COPD 40%
Heart failure 39%
Atrial fibrillation 37%
Chronic kidney disease 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 295 1,212 $5,823
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 46 4,290 $443

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $108
$108 — —
ELIQUIS
  • PFIZER INC. $41
  • E.R. Squibb & Sons, L.L.C. $17
$58 284 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $41
$41 — —
RYBELSUS
  • Novo Nordisk Inc $25
$25 — —
Ozempic
  • Novo Nordisk Inc $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record